2590-0986

Medicine in Drug Discovery

Elsevier

View prefix report (10.1016)

Health Score

0 Fair

Metadata coverage

Abstract
ORCID
References
License

Extended metadata coverage

Informational — signals of interoperability and funding across the corpus. Not part of the health score.

Funding

Funder
Award / grant

Affiliation & institutional identifiers

Affiliation
ROR ID

Update policy

Update policy

Your prioritized action plan

Ordered by how many DOIs each fix touches — start here, not with every error at once.

1

Add abstracts to 247 articles

Abstracts are what surface your work in Google Scholar, Dimensions, and OpenAlex.

High impact247 DOIs
2

Attach ORCID iDs across 193 articles

ORCID iDs strengthen author disambiguation and institutional reporting.

High impact193 DOIs
3

Deposit reference lists for 5 records

Deposited references power Crossref's Cited-by links between your articles and the literature.

Low impact5 DOIs

DOIs for this ISSN

Showing the top 5 of 247 DOIs, ordered by correction priority.

# Title Missing Priority Citations
1 Vascular Endothelial Growth Factor Receptor (VEGFR-2)/KDR In… (10.1016/j.medidd.2019.100009)
Abstract ORCID
122.89 286
2 Nano-based drug delivery systems: Conventional drug delivery… (10.1016/j.medidd.2022.100134)
Abstract ORCID
122.89 286
3 Biologics vs. small molecules: Drug costs and patient access (10.1016/j.medidd.2020.100075)
Abstract ORCID
120.07 251
4 Development and Clinical Application of Phosphorus-Containin… (10.1016/j.medidd.2020.100063)
Abstract ORCID
117.90 227
5 Piperine: A comprehensive review of methods of isolation, pu… (10.1016/j.medidd.2020.100027)
Abstract ORCID
113.36 184
6 The new SARS-CoV-2 strain shows a stronger binding affinity… (10.1016/j.medidd.2021.100086)
Abstract ORCID
110.07 158
7 Can early and high intravenous dose of vitamin C prevent and… (10.1016/j.medidd.2020.100028)
Abstract ORCID
109.79 156
8 Mesenchymal stem cells and management of COVID-19 pneumonia (10.1016/j.medidd.2020.100019)
Abstract ORCID
103.22 115
9 Combination therapy based on nano codelivery for overcoming… (10.1016/j.medidd.2020.100024)
Abstract ORCID
101.27 105
10 Serum Levels of Vitamin C and Vitamin D in a Cohort of Criti… (10.1016/j.medidd.2020.100064)
Abstract ORCID
100.85 103
11 Does vitamin D status impact mortality from SARS-CoV-2 infec… (10.1016/j.medidd.2020.100041)
Abstract ORCID
98.89 94
12 PAK1-blockers: Potential Therapeutics against COVID-19 (10.1016/j.medidd.2020.100039)
Abstract ORCID
97.95 90
13 Engineering nanoparticles to overcome the mucus barrier for… (10.1016/j.medidd.2021.100110)
Abstract ORCID
96.98 86
14 The critical role of Toll-like receptor-mediated signaling i… (10.1016/j.medidd.2022.100122)
Abstract ORCID
96.21 83
15 Recent advances in phytochemical-based Nano-formulation for… (10.1016/j.medidd.2021.100082)
Abstract ORCID
95.42 80
16 Cyclophilin A and CD147: novel therapeutic targets for the t… (10.1016/j.medidd.2020.100056)
Abstract ORCID
93.75 74
17 Antiviral performance of graphene-based materials with empha… (10.1016/j.medidd.2021.100099)
Abstract ORCID
93.17 72
18 Emerging peptide antibiotics with therapeutic potential (10.1016/j.medidd.2020.100078)
Abstract ORCID
90.65 64
19 Recent approaches in nanotoxicity assessment for drug delive… (10.1016/j.medidd.2025.100204)
Abstract ORCID
90.31 63
20 Melatonin Inhibits COVID-19-induced Cytokine Storm by Revers… (10.1016/j.medidd.2020.100044)
Abstract ORCID
89.97 62
21 Improved prediction of drug-drug interactions using ensemble… (10.1016/j.medidd.2022.100149)
Abstract ORCID
89.27 60
22 Microemulsions for enhancing drug delivery of hydrophilic dr… (10.1016/j.medidd.2023.100162)
Abstract ORCID
88.91 59
23 Vitamin D Levels and COVID-19 Susceptibility: Is there any C… (10.1016/j.medidd.2020.100051)
Abstract ORCID
88.17 57
24 Liposomes and mRNA: Two technologies together create a COVID… (10.1016/j.medidd.2021.100104)
Abstract ORCID
87.79 56
25 Generative AI for drug discovery and protein design: the nex… (10.1016/j.medidd.2025.100213)
Abstract ORCID
87.41 55
26 Inhibition of metalloproteinases in therapy for severe lung… (10.1016/j.medidd.2020.100052)
Abstract ORCID
87.02 54
27 Traditional Chinese Medicine (TCM) – Does its contemporary b… (10.1016/j.medidd.2019.100003)
Abstract ORCID
86.21 52
28 Commercial manufacturing of current good manufacturing pract… (10.1016/j.medidd.2020.100071)
Abstract ORCID
86.21 52
29 Exploring the potential of phytochemicals and nanomaterial:… (10.1016/j.medidd.2023.100151)
Abstract ORCID
86.21 52
30 Targeting Wnt/β-Catenin Pathway for Drug Therapy (10.1016/j.medidd.2020.100066)
Abstract ORCID
84.95 49
31 Network bioinformatics analysis provides insight into drug r… (10.1016/j.medidd.2021.100090)
Abstract ORCID
84.95 49
32 Molecular modelling studies for 4-oxo-1,4-dihydroquinoline-3… (10.1016/j.medidd.2019.100008)
Abstract ORCID
84.06 47
33 Sustainability in drug discovery (10.1016/j.medidd.2021.100107)
Abstract ORCID
84.06 47
34 Mechanism-based approaches of 1,3,4 thiadiazole scaffolds as… (10.1016/j.medidd.2022.100150)
Abstract ORCID
84.06 47
35 Cells and cell derivatives as drug carriers for targeted del… (10.1016/j.medidd.2020.100014)
Abstract ORCID
83.14 45
36 Overview of vaccine adjuvants (10.1016/j.medidd.2021.100103)
Abstract ORCID
82.17 43
37 Peptides in chemical space (10.1016/j.medidd.2021.100081)
Abstract ORCID
81.16 41
38 Rapidly separable microneedle patches for controlled release… (10.1016/j.medidd.2021.100118)
Abstract ORCID
81.16 41
39 The role of afferent pulmonary innervation in ARDS associate… (10.1016/j.medidd.2020.100033)
Abstract ORCID
78.99 37
40 The Delta variant mutations in the receptor binding domain o… (10.1016/j.medidd.2021.100114)
Abstract ORCID
78.99 37
41 Viral sepsis is a complication in patients with Novel Corona… (10.1016/j.medidd.2020.100057)
Abstract ORCID
78.41 36
42 Wnt/β-catenin signaling pathway in lung cancer (10.1016/j.medidd.2021.100113)
Abstract ORCID
78.41 36
43 AI drug discovery screening for COVID-19 reveals zafirlukast… (10.1016/j.medidd.2020.100077)
Abstract ORCID
77.82 35
44 Antioxidant potential of essential oils from some Himalayan… (10.1016/j.medidd.2019.100004)
Abstract ORCID
77.20 34
45 Delivery of nucleic acid therapeutics for cancer immunothera… (10.1016/j.medidd.2020.100023)
Abstract ORCID
77.20 34
46 Patient-centric design for peptide delivery: Trends in route… (10.1016/j.medidd.2020.100079)
Abstract ORCID
77.20 34
47 Rhodanine scaffold: A review of antidiabetic potential and s… (10.1016/j.medidd.2022.100131)
Abstract ORCID
77.20 34
48 Polysaccharide-Based Biomaterials for Protein Delivery (10.1016/j.medidd.2020.100031)
Abstract ORCID
75.93 32
49 Revolutionizing pharmacology: AI-powered approaches in molec… (10.1016/j.medidd.2025.100223)
Abstract ORCID
75.93 32
50 Antibody–siRNA conjugates (ARC): Emerging siRNA drug formula… (10.1016/j.medidd.2022.100128)
Abstract ORCID
75.26 31